Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
Public ClinicalTrials.gov record NCT02899299. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma
Study identification
- NCT ID
- NCT02899299
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 605 participants
Conditions and interventions
Conditions
Interventions
- Nivolumab Biological
- Ipilimumab Biological
- Pemetrexed Drug
- Cisplatin Drug
- Carboplatin Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 28, 2016
- Primary completion
- Mar 24, 2020
- Completion
- Apr 27, 2023
- Last update posted
- May 20, 2024
2016 – 2023
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ucsf | San Francisco | California | 94143 | — |
| Local Institution - 0014 | New Haven | Connecticut | 06520 | — |
| H. Lee Moffitt Cancer Center & Research Inst, Inc | Tampa | Florida | 33612 | — |
| Local Institution - 0002 | Chicago | Illinois | 60637 | — |
| Univ Of Maryland Greenbaum Cancer Center | Baltimore | Maryland | 21201 | — |
| Local Institution - 0013 | Detroit | Michigan | 48201 | — |
| Cancer & Hematology Centers Of Western Michigan | Grand Rapids | Michigan | 49503 | — |
| Local Institution - 0004 | Rochester | Minnesota | 55905 | — |
| Memorial Sloan Kettering Nassau | New York | New York | 10065 | — |
| Local Institution - 0007 | Cleveland | Ohio | 44195 | — |
| University Of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Allegheny Cancer Center | Pittsburgh | Pennsylvania | 15212 | — |
| Local Institution - 0005 | Houston | Texas | 77030 | — |
| West Virginia University | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 95 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02899299, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 20, 2024 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02899299 live on ClinicalTrials.gov.